A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with RMS.
Epistemonikos ID: 1b4b7dca15e78de4ec1662c03627c2050624fa12
First added on: Oct 09, 2025